1. Home
  2. HY vs ACRS Comparison

HY vs ACRS Comparison

Compare HY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyster-Yale Materials Handling Inc.

HY

Hyster-Yale Materials Handling Inc.

N/A

Current Price

$29.41

Market Cap

555.3M

Sector

Industrials

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.80

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HY
ACRS
Founded
1991
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
555.3M
529.9M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
HY
ACRS
Price
$29.41
$3.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
12
Target Price
★ $50.00
$10.36
AVG Volume (30 Days)
111.1K
★ 3.8M
Earning Date
11-05-2026
11-13-2026
Dividend Yield
★ 5.13%
N/A
EPS Growth
N/A
★ 69.01
EPS
N/A
★ N/A
Revenue
★ $3,769,300,000.00
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.84
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$26.41
$2.10
52 Week High
$41.30
$6.60

Technical Indicators

Market Signals
Indicator
HY
ACRS
Relative Strength Index (RSI) 44.16 41.91
Support Level $28.99 $3.18
Resistance Level $33.55 $3.86
Average True Range (ATR) 1.14 0.26
MACD 0.06 0.10
Stochastic Oscillator 46.51 67.86

Price Performance

Historical Comparison
HY
ACRS

About HY Hyster-Yale Materials Handling Inc.

Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: